Welcome to our dedicated page for Xortx Therapeutics SEC filings (Ticker: XRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XORTX Therapeutics Inc. (XRTX) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. XORTX files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These filings furnish investors with information on financial performance, clinical and regulatory progress, securities offerings, and material corporate developments related to the company’s gout and kidney disease programs.
Recent Form 6-K submissions have included condensed interim consolidated financial statements, management discussion and analysis, and officer certifications, as well as press releases describing registered direct offerings, private placements, Nasdaq minimum bid price notifications, and the binding term sheet to acquire the VB4-P5 renal anti-fibrotic program from Vectus Biosystems Limited. Certain 6-K exhibits, such as legal opinions on the validity of securities, are incorporated by reference into XORTX’s shelf registration statement on Form F-3 (File No. 333-269429).
Through this page, users can review key filing types relevant to XORTX’s sector, including 6-K reports detailing clinical and regulatory updates for the XRx-026 gout program and related XORLO™ formulation, as well as financing structures involving common shares, pre-funded warrants, and agent warrants. The filings also document the company’s responses to Nasdaq listing requirements and its use of at-the-market and registered offerings to fund development of gout, ADPKD, acute kidney injury, and diabetic nephropathy programs.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in clear language. Real-time updates from EDGAR, along with structured access to XORTX’s 6-K reports and other registered offerings, help investors quickly understand how regulatory events, financings, and clinical disclosures affect the company’s xanthine oxidase–targeted pipeline.
XORTX Therapeutics Inc. filed a Form 6-K confirming the effective details of its previously announced share consolidation. The consolidation will occur on April 6, 2026, on the basis of one new common share for every five old common shares, following approvals from the TSX Venture Exchange and Nasdaq Stock Exchange.
The company is a late-stage clinical pharmaceutical business with three clinically advanced programs targeting gout and progressive kidney diseases, plus an additional pre-clinical program for Type 2 diabetic nephropathy.
XORTX Therapeutics Inc. reported the results of its annual and special shareholder meeting held on March 24, 2026. Shareholders representing 2,407,148 common shares, approximately 35% of the shares outstanding, were present.
All items on the agenda were approved, including the election of five management nominees to the board, re-appointment of Davidson & Company LLP as auditors with directors authorized to set their pay, re-approval of the stock option plan and approval of a share consolidation.
XORTX Therapeutics Inc. reported shareholder voting results from its annual general and special meeting held on March 24, 2026. Shareholders approved setting the board at five directors and elected all nominees with strong support, including several at 100% of votes cast.
They reappointed Davidson & Co. LLP as auditor and re‑approved the stock option plan, which reserves up to 10% of issued and outstanding common shares at the grant date. Shareholders also authorized a share consolidation of up to 5 pre‑consolidation shares for 1 post‑consolidation share to help the company regain compliance with NASDAQ Capital Market continued listing requirements.
XORTX Therapeutics Inc. has postponed the effective date of its planned share consolidation. The company now expects the 1-for-5 consolidation of its common shares to take effect on April 6, 2026 instead of March 27, 2026, and it remains subject to required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange. XORTX is a late-stage clinical pharmaceutical company developing therapies for gout, autosomal dominant polycystic kidney disease, and kidney injury related to respiratory virus infections.
XORTX Therapeutics Inc. is carrying out a share consolidation, exchanging one new common share for every five existing shares to help maintain its Nasdaq listing. This 1‑for‑5 consolidation will reduce issued and outstanding shares from 6,962,218 to approximately 1,392,444.
The company will keep its current name, and its stock will continue trading on the TSX Venture Exchange and Nasdaq under the symbol XRTX on a post‑consolidation basis with a new CUSIP. All convertible securities will be proportionately adjusted, and fractional shares will be cancelled or rounded up without any cash payments.
XORTX Therapeutics Inc. reports that shareholders have approved a share consolidation, authorizing the board to combine up to five existing common shares into one new common share. The board may implement this consolidation within one year of the March 24, 2026 meeting, subject to TSX Venture Exchange approval.
The company states the primary purpose is to help maintain compliance with Nasdaq’s continued listing requirements that its shares trade above $1.00, including a condition that they trade above $1.00 for 10 days by April 13, 2026. XORTX currently has 6,962,218 common shares outstanding, which would become approximately 1,392,443 post-consolidation, depending on the treatment of fractional shares. No name change will occur, and fractional holdings will be cancelled or rounded up according to set thresholds.
XORTX Therapeutics Inc., a clinical-stage biotechnology company based in Canada and listed on Nasdaq, filed its annual report for the year ended December 31, 2025. The company focuses on kidney and metabolic diseases using small-molecule drugs.
XORTX reported net losses of US$2,158,065 in 2023, US$3,313,346 in 2024 and US$2,656,304 in 2025, with an accumulated deficit of about US$23,824,557 as of December 31, 2025. It has no approved products and has not generated revenue from product sales.
The lead program, XRx-026 for gout, is the most advanced; XRx-008 for ADPKD holds U.S. Orphan Drug Designation, and XRx-101 targets acute kidney injury linked to respiratory virus infections. Management warns it expects continued losses, needs substantial additional funding, faces significant clinical, regulatory and commercialization risks, and could experience share price volatility with potential dilution for shareholders.
XORTX Therapeutics Inc. has proposed three new director nominees for election at its March 24, 2026 annual and special shareholder meeting. George Scorsis, Richard Grieve and Mika Grasso will stand for election in place of three current nominees.
The change is tied to a significant financing initiative, which requires these new directors to join the board as a condition of closing and remains subject to TSX Venture Exchange approval. If the financing is not completed, the new directors will resign and the resulting vacancies will be filled later by the company.
Management proxies will be voted in favour of the new nominees unless shareholders withhold votes. The board unanimously recommends voting for all resolutions, while XORTX continues advancing late-stage programs targeting gout and progressive kidney disease.
XORTX Therapeutics Inc. filed a Form 6-K highlighting that independent proxy advisory firms, including Institutional Shareholder Services (ISS), have recommended that shareholders vote “FOR” the proposed share consolidation at the upcoming shareholder meeting on March 24, 2026. The company’s board of directors unanimously recommends that shareholders vote for all resolutions.
The proxy voting deadline is March 20, 2026, and shareholders of record as of the close of business on February 20, 2026 are eligible to vote. Laurel Hill Advisory Group has been engaged to provide voting assistance. XORTX also reiterates its late-stage clinical pipeline in gout, ADPKD, acute kidney injury and diabetic nephropathy.
XORTX Therapeutics Inc. filed a Form 6-K to notify shareholders that meeting materials for its upcoming Annual and Special Meeting are now available and have been mailed. The meeting will be held on March 24, 2026 at 10:00 a.m. Calgary time at the company’s Calgary offices.
Shareholders of record as of February 20, 2026 will vote on fixing the board at five directors, electing directors, appointing the auditor and authorizing its remuneration, confirming and approving the stock option plan, and an ordinary resolution to amend the articles to allow a consolidation of the common shares on the basis of up to five pre-consolidation shares for one post-consolidation share. The board unanimously recommends voting for all items, and proxy voting closes on March 20, 2026.